Opinion|Videos|July 29, 2024
COBRA: Rates of ctDNA Clearance in Assay-Directed Therapy
Author(s)Stacey A. Cohen, MD, Daniel H. Ahn, DO
Daniel H. Ahn, DO, and Stacey A. Cohen, MD, discuss the COBRA clinical trial, which evaluated rates of ctDNA clearance in patients with colorectal cancer receiving assay-directed therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
3
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
4
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
5